Scinai Immunotherapeutics Ltd. (NASDAQ:SCNI) Sees Significant Increase in Short Interest

Scinai Immunotherapeutics Ltd. (NASDAQ:SCNI) was the target of a significant growth in short interest in March. As of March 15th, there was short interest totalling 3,700 shares, a growth of 117.6% from the February 28th total of 1,700 shares. Approximately 1.1% of the shares of the stock are sold short. Based on an average daily volume of 10,700 shares, the days-to-cover ratio is currently 0.3 days.

Scinai Immunotherapeutics Price Performance

NASDAQ:SCNI traded down $0.10 on Friday, reaching $2.80. 4,626 shares of the company’s stock traded hands, compared to its average volume of 278,022. The stock has a 50-day simple moving average of $3.41 and a 200-day simple moving average of $3.45. Scinai Immunotherapeutics has a 12 month low of $2.23 and a 12 month high of $8.92. The firm has a market cap of $2.62 million, a PE ratio of -0.01 and a beta of 2.36. The company has a quick ratio of 1.16, a current ratio of 1.16 and a debt-to-equity ratio of 0.06.

Scinai Immunotherapeutics Company Profile

Scinai Immunotherapeutics Ltd., a development stage biopharmaceutical company, focuses on developing, manufacturing, and commercializing products for the prevention and treatment of infectious and autoimmune diseases in Israel. It has licensing and collaboration agreement with Max Planck Society and University Medical Center Göttingen for the development and commercialization of COVID-19 nanosized antibody (NanoAb); and development and commercialization of NanoAbs for various other disease indications.